Abbott MediaRoom (Product) http://abbott.mediaroom.com/ Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening http://abbott.mediaroom.com/2018-04-23-Sanquin-Selects-Abbotts-Alinity-TM-s-Solution-for-Blood-and-Plasma-Screening LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS Mon, 23 Apr 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-04-23-Sanquin-Selects-Abbotts-Alinity-TM-s-Solution-for-Blood-and-Plasma-Screening Abbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals http://abbott.mediaroom.com/2018-04-17-Abbotts-New-Ensure-R-Max-Protein-Helps-Americans-Go-for-Their-HealthGoals - Protein is all the rage but new data shows adults 50+ are still missing the mark Tue, 17 Apr 2018 09:30:00 -0400 http://abbott.mediaroom.com/2018-04-17-Abbotts-New-Ensure-R-Max-Protein-Helps-Americans-Go-for-Their-HealthGoals Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor http://abbott.mediaroom.com/2018-03-29-Abbott-Initiates-Trial-to-Evaluate-Improved-Survival-And-Outcomes-with-the-CardioMEMS-Monitor - THE CARDIOMEMS™ HF SYSTEM IS THE FIRST AND ONLY FDA-APPROVED HEART FAILURE MONITOR PROVEN TO SIGNIFICANTLY REDUCE HEART FAILURE HOSPITAL ADMISSIONS AND IMPROVE QUALITY OF LIFE Thu, 29 Mar 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-03-29-Abbott-Initiates-Trial-to-Evaluate-Improved-Survival-And-Outcomes-with-the-CardioMEMS-Monitor Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation http://abbott.mediaroom.com/2018-03-19-Abbotts-MitraClip-Therapy-Receives-National-Reimbursement-in-Japan-to-Treat-Patients-with-Mitral-Regurgitation - National reimbursement adds the device into Japan's health insurance system, which enables greater access for patients Mon, 19 Mar 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-03-19-Abbotts-MitraClip-Therapy-Receives-National-Reimbursement-in-Japan-to-Treat-Patients-with-Mitral-Regurgitation New Long-Term Data Show Improved Survival and Lower Rates of Stroke and Pump Thrombosis for Abbott's HeartMate 3 Heart Pump http://abbott.mediaroom.com/2018-03-11-New-Long-Term-Data-Show-Improved-Survival-and-Lower-Rates-of-Stroke-and-Pump-Thrombosis-for-Abbotts-HeartMate-3-Heart-Pump -- HEARTMATE 3™ LVAD DEMONSTRATED IMPROVED CLINICAL OUTCOMES OVER THE MOST WIDELY USED LVAD IN THE WORLD Sun, 11 Mar 2018 10:59:00 -0400 http://abbott.mediaroom.com/2018-03-11-New-Long-Term-Data-Show-Improved-Survival-and-Lower-Rates-of-Stroke-and-Pump-Thrombosis-for-Abbotts-HeartMate-3-Heart-Pump